Overview

Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of bavituximab when administered via a vein as a single infusion and to examine how bavituximab behaves in the body and how it affects the amount of hepatitis C virus in individuals with chronic infection.
Phase:
Phase 1
Details
Lead Sponsor:
Peregrine Pharmaceuticals
Treatments:
Antibodies, Monoclonal
Bavituximab